期刊
DRUGS OF TODAY
卷 55, 期 12, 页码 743-752出版社
PROUS SCIENCE, SAU-THOMSON REUTERS
DOI: 10.1358/dot.2019.55.12.3058861
关键词
Triclabendazole; Fascioliasis; Treatment of helminthic diseases; Anti-infective therapy; Anthelmintic drugs
Fascioliasis is a neglected tropical disease that is commonly caused by flatworms affecting both domestic ruminants and humans. Fascioliasis currently affects -17 million people globally with additional 180 million people at risk of developing infection. Despite the gigantic patient pool, clinicians typically have very few treatment options available. In this context, triclabendazole (Fasinex, Egaten) is the only medication approved by the Food and Drug Administration (FDA) for the treatment of fascioliasis. The FDA approval has been granted in 2019 although the drug was already utilized in the veterinary setting. Recently, three hits from the Pathogen Box have been identified in vitro as exhibiting potent anti-fascioliasis activity in an effort to identify other drugs active against fascioliasis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据